Subscribe to Search results

Dr Mitchell understood from the 1978 Sheffield study in some patients liver disease was significant and progressive. He decided to restrict the use of large donor pool concentrates whenever possible in order to liver disease.

Published on:

Dr Mitchell argued "recurrent treatment with blood products is hazardous... The best approach seems to us to be a treatment policy" designed to reduce all the risks associated with blood products and is tailored to the needs of individual patients.

Published on:

Haemophilia B was referred to "Christmas disease" after the name of the first patient whose condition was examined in detail.

Published on:

Prior to 1952 patients were categorised under a generic diagnosis of haemophilia, but by 1952 Haemophilia B could be identified separately from Haemophilia A.

Published on:

It was stated that the "The biological roles of Factors 8 and 9 are closely related...and so the clinical picture that is caused by these deficiencies is near identical."

Published on:

An application for renewal of product licence Proplex Factor IX Complex was made from Travenol Laboratories

Published on:

Proplex Factor IX Complex (Human) was granted a product licence

Published on:

Authority was given for the grant of a product licence for Proplex Factor IX Complex

Published on:

Table provided Protein Fraction Centre licences updates and renewals

Published on:

Part II Licensing granted authority for products including 'dried human antihemophilic fraction' and 'dried human factor IX fraction'

Published on:

As the 1970s progressed, home therapy with Factor 9 concentrates became a feature of the treatment of people with Haemophilia B

Published on:

Newsletter

Published on:

By 1979, the issue of chronic hepatitis dominated everyone's lives.

Published on:

Dr Forbes said that by 1983, doctors were already starting to observe patients to see if there were early signs of AIDS.

Published on:

Dr Forbes acknowledged in 1983 that there was the potential for locally sourced donors to bring contaminated blood with HIV into the donor pool.

Published on:

The Belfast Haemophilia Centre was established in 1958 but until 1981 it was included in the Oxford supra-region.

Published on:

At the meeting of the Haemophilia reference centre directors held on 14 September 1981, it was noted that the annual returns for 1980 showed that the amount of Factor VIII concentrates used, especially commercial materials, had again increased.

Published on:

Dr Elizabeth Mayne became director of the Belfast Haemophilia Centre.

Published on:

Dr Mayne describing the history of haemophilia care in Northern Ireland, described patients as being "ecstatic" with the advent of cryoprecipitate which was "revolutionary".

Published on:

Hemofil was the commercial concentrate used in Belfast Haemophilia Centre

Published on: